PDCD1 and colorectal carcinoma: Furthermore, we observe significant synergy between TMPyP4 and anti-PD1 immunotherapy, particularly beneficial for CRC patients with microsatellite-stable (MSS) tumors, who typically exhibit limited responses to immunotherapy alone.